Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

628
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
628
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.4K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

484
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

588
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
588
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

229
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
229

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.

Cardiology and therapy·2024
Same author

Abdominal Congestion as a Predictor of Worsening Renal Function in Patients With Acute Decompensated Heart Failure.

Journal of the Saudi Heart Association·2024
Same author

Left Ventricular Remodeling Following Balloon Mitral Valvuloplasty in Rheumatic Mitral Stenosis: Magnetic Resonance Imaging Study.

Frontiers in cardiovascular medicine·2021
Same author

Left atrial structural and functional remodeling following balloon mitral valvuloplasty.

The international journal of cardiovascular imaging·2020
Same author

Acute coronary syndromes in developing countries during the COVID-19 pandemic.

European heart journal·2020
Same author

New renal haemodynamic indices can predict worsening of renal function in acute decompensated heart failure.

ESC heart failure·2020

Related Experiment Video

Updated: Apr 20, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

897

Riociguat: PATENT-1 Study.

Karim Said1

  • 1Aswan Heart Centre, Aswan, Egypt, Aswan, Egypt.

Global Cardiology Science & Practice
|November 19, 2014
PubMed
Summary
This summary is machine-generated.

Soluble guanylate cyclase (sGC) stimulators, like riociguat, are new treatments for pulmonary arterial hypertension. The PATENT-1 study supported riociguat

More Related Videos

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography
07:23

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography

Published on: March 26, 2020

9.2K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.7K

Related Experiment Videos

Last Updated: Apr 20, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

897
Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography
07:23

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography

Published on: March 26, 2020

9.2K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.7K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Pulmonology

Background:

  • Soluble guanylate cyclase (sGC) stimulators represent a novel class of pharmacological agents.
  • Research has advanced to develop more potent and specific sGC stimulators, exemplified by riociguat.
  • Pulmonary arterial hypertension (PAH) is a serious condition requiring effective treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of riociguat in adult patients with pulmonary arterial hypertension.
  • To provide clinical trial data supporting the recent FDA approval of riociguat for PAH treatment.

Main Methods:

  • The study involved adult patients diagnosed with pulmonary arterial hypertension.
  • Patients received treatment with riociguat, a potent and specific sGC stimulator.
  • The PATENT-1 trial was designed to assess the drug's performance in a clinical setting.

Main Results:

  • The PATENT-1 study provided key evidence supporting the efficacy of riociguat.
  • Results from this trial were instrumental in the US FDA's approval of riociguat.
  • Riociguat demonstrated effectiveness in treating adult patients with pulmonary arterial hypertension.

Conclusions:

  • Riociguat is an approved pharmacological agent for treating pulmonary arterial hypertension in adults.
  • The PATENT-1 study is a significant clinical trial that underpinned riociguat's approval.
  • sGC stimulators, including riociguat, offer a new therapeutic avenue for PAH management.